A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia
This study is looking into a new treatment called QTX-2101, used alongside a common medicine called All-trans Retinoic Acid, for people newly diagnosed with a specific type of blood cancer known as Acute Promyelocytic Leukemia (APL). The main goal is to understand how well the body handles QTX-2101 and how effective this combination is at getting rid of the cancer cells. Researchers will be checking if the cancer completely disappears at a genetic level and looking at side effects. This is a Phase 3 study, meaning it's a key step to see if this new treatment can become widely available and improve care for APL patients.
En un coup d'œil
De quoi parle cette étude ?
This clinical trial is focused on a type of blood cancer called Acute Promyelocytic Leukemia (APL). APL is a serious condition where there are too many immature white blood cells in the bone marrow. Standard treatments for APL often include medicines like All-trans Retinoic Acid. This study is testing a new drug, QTX-2101, in combination with All-trans Retinoic Acid to see if it can be an even more effective treatment for people who have just been diagnosed with APL.
The main aim of the study is to understand two key things. Firstly, how the body processes QTX-2101 (this is called 'PK parameters'). This helps doctors figure out the best dose and how often the medicine should be given. Secondly, and very importantly, the study wants to see how effective the treatment is at achieving 'molecular complete remission'. This means checking if the specific cancer gene (PML/RARA) that causes APL disappears entirely from the bone marrow, using highly sensitive tests.
Beyond these main goals, researchers will also be carefully monitoring for any side effects, how the treatment impacts quality of life, and overall survival rates. This study is a 'Phase 3' trial, which means it's one of the final steps before a new treatment can be considered for wider use. The results from this research could potentially lead to a new and better way to treat APL.
Points clés
- This study is testing a new drug (QTX-2101) for newly diagnosed APL.
- It combines the new drug with an existing standard treatment for APL.
- The main goals are to check the drug's safety and how well it clears cancer cells.
- Participation involves regular hospital visits for medication and tests.
- The study also looks at how the treatment impacts your quality of life.
Qui peut être éligible ?
To join this study, you would need to be an adult, 18 years of age or older, and have a new diagnosis of a specific type of blood cancer called Acute Promyelocytic Leukemia (APL). Both men and women are welcome to participate.
There will be other detailed medical criteria that the study doctors will check to make sure the trial is safe and appropriate for you. For example, they'll look at your general health, other medical conditions you might have, and any other medications you are taking. This is to ensure that the study is a good fit for your individual situation.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Have you recently been diagnosed with Acute Promyelocytic Leukemia (APL)?
- Are you generally in good health, apart from your APL diagnosis?
- Are you able to attend regular hospital appointments for treatment and tests?
En quoi consiste la participation ?
If you decide to participate in this study, you will receive the new drug QTX-2101, along with the standard treatment for APL. This will involve regular visits to the hospital for infusions of the medication and various tests. These tests include blood samples to check how your body is handling the medication and how the cancer is responding. There will also be bone marrow biopsies to specifically look for the cancer gene, and regular heart checks (ECGs) to monitor your heart health.
You will also be asked to fill out questionnaires about your quality of life, how convenient you find the treatment, and your overall satisfaction, to help researchers understand the patient experience. The total duration of your participation will depend on your individual response to the treatment, but studies like this typically involve several months of active treatment and then follow-up appointments.
Risques et avantages potentiels
Emplacements (6)
- —Non vérifiéAllemagne
- —Non vérifiéPologne
- —Non vérifiéEspagne
- —Non vérifiéRoumanie
- —Non vérifiéItalie
- —Non vérifiéFrance
Questions fréquentes
What is Acute Promyelocytic Leukemia (APL)?
APL is a specific type of blood cancer that affects the white blood cells in your body.
What is QTX-2101?
QTX-2101 is a new drug being investigated in combination with standard treatment for APL.
What does a 'Phase 3' study mean?
It means this is one of the final steps to see if a new treatment is safe and effective enough to be approved for wider use.
Will I receive the new drug, or a placebo?
In this specific study, all participants will receive the new drug QTX-2101 along with the existing standard treatment.
What is 'molecular complete remission'?
It means the specific cancer gene linked to APL cannot be detected in your bone marrow using very sensitive tests.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.